Kazia Therapeutics Ltd (ASX: KZA) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Kazia Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $36.23 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 139.33 million
Earnings per share -0.111
Dividend per share N/A
Year To Date Return -80.08%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Kazia Therapeutics Ltd (ASX: KZA)
Latest News

A young businesswoman looks shocked at what she's reading on the paperwork in her hand, with colleagues in the office in the background.
Share Fallers

This ASX healthcare share just crashed 49%, here’s why

Kazia's GBM Agile pivotal study has encountered a roadblock.

Read more »

two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market
Healthcare Shares

3 ASX healthcare shares with big news coming

The next 6 months could see these companies welcome huge milestones that could send stocks rocketing.

Read more »

Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22
Healthcare Shares

Here’s why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today

Kazia's investigational drug, Paxalisib, is set to be involved in its ninth ongoing clinical study.

Read more »

Biotechnology graphics
Healthcare Shares

Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today

The global effort to defeat cancer continues, with this ASX healthcare share commencing a new clinical study.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Share Market News

Kazia (ASX:KZA) share price slides despite positive update

The Kazia Therapeutics Ltd (ASX: KZA) share price is backtracking today despite announcing encouraging data from its paxalisib phase II…

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Share Market News

Why the Kazia Therapeutics (ASX:KZA) share price is rocketing 11%

The Kazia Therapeutics Ltd (ASX:KZA) share price is shooting for the moon after the company announced a licence agreement in…

Read more »

biotech shares
Share Market News

Why Kazia Therapeutics share price has skyrocketed today

The Kazia Therapeutics share price has soared after gaining US Food and Drug Administration approval to fast-track its drug trials

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Share Market News

Kazia Therapeutics share price soars 46% on new drug grant

The Kazia Therapeutics share price is today storming higher as a release indicates a new FDA grant for its flagship…

Read more »

KZA ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Kazia Therapeutics Ltd

Formerly Norvet Limited (NRT), 30/04/1997 ; Novogen Limited (NRT), 28/11/2017

KZA Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
08 Aug 2022 $0.26 $0.01 4.00% 1,213,546 $0.28 $0.30 $0.26
05 Aug 2022 $0.25 $0.02 8.51% 993,124 $0.24 $0.27 $0.24
04 Aug 2022 $0.24 $-0.01 -4.08% 435,568 $0.25 $0.25 $0.23
03 Aug 2022 $0.25 $0.00 0.00% 246,128 $0.25 $0.25 $0.24
02 Aug 2022 $0.25 $0.01 4.17% 901,778 $0.25 $0.26 $0.24
01 Aug 2022 $0.24 $-0.27 -52.94% 2,609,438 $0.35 $0.35 $0.23
29 Jul 2022 $0.51 $0.02 4.04% 32,662 $0.52 $0.53 $0.51
28 Jul 2022 $0.50 $-0.04 -7.55% 247,907 $0.52 $0.52 $0.50
27 Jul 2022 $0.53 $0.02 3.92% 230,402 $0.52 $0.55 $0.50
26 Jul 2022 $0.51 $-0.01 -1.94% 16,861 $0.51 $0.54 $0.50
25 Jul 2022 $0.52 $-0.04 -7.27% 67,165 $0.55 $0.56 $0.50
22 Jul 2022 $0.55 $-0.04 -6.72% 86,279 $0.58 $0.58 $0.55
21 Jul 2022 $0.60 $0.05 9.17% 57,682 $0.57 $0.60 $0.56
20 Jul 2022 $0.55 $0.05 10.00% 72,449 $0.51 $0.57 $0.51
19 Jul 2022 $0.50 $-0.04 -7.41% 324,575 $0.56 $0.56 $0.49
18 Jul 2022 $0.54 $-0.02 -3.57% 148,773 $0.57 $0.58 $0.53
15 Jul 2022 $0.56 $-0.02 -3.45% 122,392 $0.60 $0.60 $0.55
14 Jul 2022 $0.58 $-0.03 -4.92% 120,851 $0.60 $0.60 $0.58
13 Jul 2022 $0.61 $-0.01 -1.63% 57,126 $0.62 $0.63 $0.60
12 Jul 2022 $0.62 $0.01 1.64% 72,838 $0.61 $0.65 $0.61
11 Jul 2022 $0.61 $-0.01 -1.61% 35,766 $0.64 $0.64 $0.61

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Dec 2021 Steven Coffey Buy 50 $54,154
On-market trade.
20 Dec 2021 Bryce Carmine Buy 47 $50,470
On-market trade.
16 Dec 2021 Iain Ross Buy 50 $53,150
On-market trade.
16 Dec 2021 James Garner Buy 50 $53,864
On-market trade.
27 Aug 2021 James Garner Buy 20 $27,623
On-market trade.
27 Aug 2021 Iain Ross Buy 25 $34,250
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Steven Roy Stent Coffey Non-Executive Director Nov 2012
Mr Coffey is a Chartered Accountant and registered company auditor and has over 35 years experience in the accounting and finance industry. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993. He sits on the board of a number of large private family companies and audits a number of large private companies and not-for-profit entities. He is Chair of Audit, Risk and Governance Committee, Member of Remuneration and Nomination Committee
Mr Iain Ross Non-Executive DirectorNon-Executive Chairman Jul 2015
Mr Ross, based in the UK, is an experienced Director and has served on a number of Australian company boards. He is Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited. He is also a non-executive director of Palla Pharma Limited (ASX:PAL). In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. His track record includes financing transactions having raised in excess of euros 400 million, both publicly and privately, as well as experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim Other current directorships held by him are Silence Therapeutics plc (LSE:SLN), ReNeuron Group plc (LSE:RENE), Palla Pharma Limited (ASX:PAL) and BiVictriX Therapeutics plc (LSE:BVX) Former directorships (last 3 years): Redx Pharma plc (LSE:REDX), Premier Veterinary Group Plc (LSE:PVG), Anatara Lifesciences Limited (ASX:ANR) and e-Therapeutics plc (LSE:ETX). He is a Member of Remuneration and Nomination Committee, Member of Audit, Risk and Governance Committee.
Mr Bryce Carmine Non-Executive Director Jun 2015
Ms Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company's Executive Committee. Mr Carmine previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. During his career with Lilly, Ms Carmine held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. Ms Carmine is currently Chairman and CEO of HaemaLogiX Pty Ltd, a Sydney based privately owned biotech. He is a Member of Audit, Risk and Governance Committee, Chair of Remuneration and Nomination Committee.
Dr James Garner Chief Executive OfficerManaging Director Feb 2016
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. Dr Garner is a physician by training. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.
Ms Catherine (Kate) Jane Hill Company Secretary Sep 2016
Catherine (Kate) Jane Hill Company Secretary
Gabrielle Heaton Director of Finance and Administration

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 52,263,824 40.32%
Willoughby Capital Pty Ltd <Willoughby Capital A/C> 15,500,000 11.96%
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 5,951,957 4.59%
Bnp Paribas Noms Pty Ltd <Drp> 5,342,372 4.12%
Citicorp Nominees Pty Limited 2,926,720 2.26%
Mna Family Holdings Pty Ltd <Hishenk Pty Ltd Super A/C> 1,920,000 1.48%
Netwealth Investments Limited <Wrap Services A/C> 1,384,872 1.07%
BNP Paribas Nominees Pty Ltd Acf Clearstream 1,316,415 1.02%
Hishenk Pty Ltd 1,295,000 1.00%
Jamplat Pty Ltd 1,293,334 1.00%
Mr Iain Ross 1,000,001 0.77%
Mr Peter Alan Luedeke + Mrs Julia Luedeke <Luedeke Retirement Fund A/C> 650,000 0.50%
Mr Francis Samson 570,000 0.44%
Mr Tony Mark Eldridge + Mrs Anita Maree Eldridge <Tm & Am Eldridge Super A/C> 555,000 0.43%
National Nominees Limited 506,172 0.39%
D & G Brown Investments Pty Limited 503,589 0.39%
C & L Jackson Investments Pty Ltd <Jackson Family S/Fund A/C> 479,001 0.37%
Invia Custodian Pty Limited <Gsjbw Managed A/C> 454,988 0.35%
El Coronado Holdings 453,164 0.35%
Mr Ross Richard Eddison 450,000 0.35%